-
Codexis (CDXS) Tops Q4 EPS by 15c, Beats on Revenue
-
Codexis signs lease for 34,000 square foot GMP manufacturing facility
-
Codexis (CDXS) Misses Q3 EPS by 7c, Misses on Revenue
-
Codexis partners with Nitto Denko Avecia on siRNA manufacturing platform
-
Benchmark Reiterates Hold Rating on Codexis, Inc. (CDXS)
-
Stifel on Codexis, Inc. (CDXS): 'Key Milestones On the Horizon in 2H25'
-
Cantor Fitzgerald Reiterates Overweight Rating on Codexis, Inc. (CDXS)
-
Codexis (CDXS) Tops Q2 EPS by 3c
-
Stifel Reiterates Buy Rating on Codexis, Inc. (CDXS)
-
Codexis (CDXS) Misses Q1 EPS by 1c, Misses on Revenue; Offers FY25 Revenue Guidance
-
Codexis (CDXS) Announces Retirement of Byron Dorgan from Board
-
Codexis (CDXS) Appoints Cynthia Collins to its Board
-
Craig Hallum on Codexis (CDXS): 'We believe investors should buy this stock'
-
Codexis (CDXS) announces inducement grants for two new employees
-
Codexis (CDXS) Misses Q4 EPS by 9c, Misses on Revenue; Offers FY25 Revenue Guidance
-
Codexis (CDXS) Appoints Arthur Levin to Strategic Advisory Board
-
Codexis (CDXS) Appoints Christos Richards to its Board
-
Codexis (CDXS) Appoints Raymond De Vre to its Board
-
Codexis (CDXS) Misses Q3 EPS by 5c, reiterates guidance
-
Artiva Biotherapeutics (ARTV) Appoints Alison Moore to its Board
-
Codexis (CDXS) Increases Cash Reserves and Enhances Management Team to Fuel Growth of Company
-
Codexis (CDXS) Licenses Genomics Life Science Enzyme Portfolio to Alphazyme
-
Piper Sandler Reiterates Overweight Rating on Codexis, Inc. (CDXS)

